Biomet became aware of violations in October 2013 and conducted an internal investigation. The executives and employees involved in the violations were disciplined or terminated and the company discussed the situation with the Securities and Exchange Commission in April last year.
The investigation is ongoing, but the DOJ could bring further actions against Biomet if the DOJ determines the company’s activities breached the deferred prosecution agreement. The agreement is extended for another year.
More articles on orthopedic devices:
Greatbatch short interest drops by 8.5% — 4 things to know
Amedica to present CASCADE clinical results
Spine device stock report: 5 key companies
